Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| ARST0431 | COG | Intensive Multi-Agent Therapy; Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma: A Groupwide Phase III Study | Pediatric CIRB | Completed | |
| ARST0531 | COG | Randomized Study of Vincristine; Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS): A Groupwide Phase III Study | Pediatric CIRB | Completed | |
| ARST08P1 | COG | A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12; Anti-IGF-IR Monoclonal Antibody; IND #100947; NSC # 742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma: A Groupwide Pilot Study | Pediatric CIRB | Completed | |
| ARST0921 | COG | A Randomized Phase II Trial of Bevacizumab (IND# 7921; Avastin) and Temsirolimus (IND# 61010; Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma: A Groupwide Phase II Study | Pediatric CIRB | Completed | |
| ARST1321 | COG | Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754; IND# 118613) | Pediatric CIRB | Available to Open | |
| ARST1431 | COG | A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) | Pediatric CIRB | Available to Open | |
| ARST1921 | COG | A Safety, Pharmacokinetic and Efficacy Study of a γ-Secretase Inhibitor, Nirogacestat (PF 03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors | Pediatric CIRB | Available to Open | |
| ARST2031 | COG | A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS) | Pediatric CIRB | Available to Open | |
| ARST2032 | COG | A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma | Pediatric CIRB | Available to Open | |
| ASCT0431 | COG | A Randomized Trial of Sirolimus-Based Graft versus Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation in Selected Patients with CR1 and CR2 ALL: A Groupwide Phase III Study | Pediatric CIRB | Completed |